Isomorphic Labs, Alphabet's drug discovery subsidiary led by Demis Hassabis, raised $5 billion in a Series C funding round co-led by Sequoia Capital and Greenoaks on November 17, 2026. Coming six months after a $2.1 billion raise, the capital will fund the platform's expansion into biologics and accelerate preclinical oncology work toward clinical trials. Despite compute market anxieties following Jensen Huang's resignation from Nvidia, Isomorphic relies on custom Google chips to scale model development.
Nov 16, 2026 · 3 sources
Nov 17, 2026 · 2 sources
Nov 13, 2026 · 3 sources
Nov 17, 2026 · 3 sources
Story comments
Loading comments…